{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T19:21:16Z","timestamp":1696360876585},"reference-count":18,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.leukres.2009.12.023","type":"journal-article","created":{"date-parts":[[2010,1,15]],"date-time":"2010-01-15T05:55:00Z","timestamp":1263534900000},"page":"700-701","source":"Crossref","is-referenced-by-count":1,"title":["Bortezomib down-regulates the osterix expression by osteoblasts in the myeloma microenvironment: Implications into osteoblast function in myeloma bone disease"],"prefix":"10.1016","volume":"34","author":[{"given":"Evangelos","family":"Terpos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2009.12.023_bib1","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/annonc\/mdi235","article-title":"Myeloma bone disease: pathophysiology and management","volume":"16","author":"Terpos","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.leukres.2009.12.023_bib2","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2009.12.023_bib3","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1182\/blood-2004-12-4940","article-title":"Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2","volume":"106","author":"Oshima","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.12.023_bib4","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood-2004-12-4986","article-title":"Myeloma cells block RUNX2\/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation","volume":"106","author":"Giuliani","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.12.023_bib5","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1002\/ijc.22033","article-title":"Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation","volume":"119","author":"Politou","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.leukres.2009.12.023_bib6","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/annonc\/mdn796","article-title":"The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network","volume":"20","author":"Terpos","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.leukres.2009.12.023_bib7","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1517\/17425255.4.5.639","article-title":"Bortezomib in multiple myeloma","volume":"4","author":"Terpos","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.leukres.2009.12.023_bib8","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1182\/blood-2007-03-067710","article-title":"Myeloma bone disease and proteasome inhibition therapies","volume":"110","author":"Terpos","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.12.023_bib9","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood-2006-11-059188","article-title":"The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients","volume":"110","author":"Giuliani","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.12.023_bib10","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1365-2141.2006.06356.x","article-title":"Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma","volume":"135","author":"Terpos","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2009.12.023_bib11","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/sj.leu.2404806","article-title":"Bortezomib inhibits human osteoclastogenesis","volume":"21","author":"von Metzler","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2009.12.023_bib12","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.leukres.2008.02.019","article-title":"Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions","volume":"32","author":"Boissy","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2009.12.023_bib13","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1038\/leu.2008.235","article-title":"The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed\/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis","volume":"22","author":"Terpos","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2009.12.023_bib14","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/blood.V114.22.425.425","article-title":"High serum sclerostin correlates with advanced stage, increased bone resorption, reduced osteoblast function, and poor survival in newly diagnosed patients with multiple myeloma","volume":"114","author":"Terpos","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.12.023_bib15","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.leukres.2009.07.017","article-title":"Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: In vitro effect of Bortezomib and Lenalidomide","volume":"34","author":"De Matteo","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2009.12.023_bib16","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1146\/annurev.genom.9.081307.164437","article-title":"Transcriptional control of skeletogenesis","volume":"9","author":"Karsenty","year":"2008","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1016\/j.leukres.2009.12.023_bib17","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/sj.leu.2404843","article-title":"The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma","volume":"21","author":"Terpos","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2009.12.023_bib18","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood.V114.22.1815.1815","article-title":"The addition of bortezomib to the combination of lenalidomide and dexamethasone increases bone formation in relapsed\/refractory myeloma: a prospective study in 91 patients","volume":"114","author":"Terpos","year":"2009","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212609006055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212609006055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T20:04:42Z","timestamp":1590523482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212609006055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0145212609006055"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2009.12.023","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}